Method for screening for a cancer treatment agent using the interaction between PAUF and a binding partner thereof

    公开(公告)号:US10023915B2

    公开(公告)日:2018-07-17

    申请号:US14008537

    申请日:2011-08-02

    摘要: The present invention relates to a method for screening for a cancer treatment agent by contacting a test material with pancreatic adenocarcinoma upregulated factor (PAUF) and GLRX3, SNAPIN, or UBL4A, as a binding partner for PAUF, and then analyzing whether or not the test material inhibits the binding of the PAUF and GLRX3, SNAPIN, or UBL4A serving as a binding partner therefor, thereby determining that the test material is a cancer treatment agent if the binding is inhibited. The invention also relates to a pharmaceutical composition containing the test material as an active ingredient for inhibiting and treating cancer. The pharmaceutical composition of the present invention, which contains, as an active ingredient, an inhibitor for inhibiting PAUF from binding with a binding partner, effectively inhibits PAUF signaling related to the onset of cancer, thus enabling various kinds of cancer (especially pancreatic cancer) to be treated.

    METHOD FOR SCREENING FOR A CANCER TREATMENT AGENT USING THE INTERACTION BETWEEN PAUF AND A BINDING PARTNER THEREOF
    3.
    发明申请
    METHOD FOR SCREENING FOR A CANCER TREATMENT AGENT USING THE INTERACTION BETWEEN PAUF AND A BINDING PARTNER THEREOF 有权
    用于使用PAUF与其结合合作伙伴之间的相互作用的癌症治疗剂进行筛选的方法

    公开(公告)号:US20140018304A1

    公开(公告)日:2014-01-16

    申请号:US14008537

    申请日:2011-08-02

    IPC分类号: C12Q1/68 G01N33/68

    摘要: The present invention relates to a method for screening for a cancer treatment agent by contacting a test material with pancreatic adenocarcinoma upregulated factor (PAUF) and GLRX3, SNAPIN, or UBL4A, as a binding partner for PAUF, and then analyzing whether or not the test material inhibits the binding of the PAUF and GLRX3, SNAPIN, or UBL4A serving as a binding partner therefor, thereby determining that the test material is a cancer treatment agent if the binding is inhibited. The invention also relates to a pharmaceutical composition containing the test material as an active ingredient for inhibiting and treating cancer. The pharmaceutical composition of the present invention, which contains, as an active ingredient, an inhibitor for inhibiting PAUF from binding with a binding partner, effectively inhibits PAUF signaling related to the onset of cancer, thus enabling various kinds of cancer (especially pancreatic cancer) to be treated.

    摘要翻译: 本发明涉及通过使测试材料与胰腺腺癌上调因子(PAUF)和GLRX3,SNAPIN或UBL4A作为PAUF的结合配偶体接触来筛选癌症治疗剂的方法,然后分析是否测试 材料抑制作为其结合配偶体的PAUF和GLRX3,SNAPIN或UBL4A的结合,从而确定如果结合被抑制,则测试材料是癌症治疗剂。 本发明还涉及含有作为抑制和治疗癌症的活性成分的测试材料的药物组合物。 含有抑制PAUF与结合配偶体结合的抑制剂作为活性成分的本发明的药物组合物能够有效抑制与癌症发生有关的PAUF信号传导,从而能够进行各种癌症(尤其是胰腺癌) 待处理

    Apparatus for rejecting image in receiver
    5.
    发明授权
    Apparatus for rejecting image in receiver 失效
    用于在接收机中拒绝图像的装置

    公开(公告)号:US08300744B2

    公开(公告)日:2012-10-30

    申请号:US12695860

    申请日:2010-01-28

    IPC分类号: H03D1/04

    摘要: The present invention relates to an apparatus for rejecting images in a receiver.The apparatus of the present invention relates to an apparatus for rejecting image signals in a receiver of a direct conversion structure and comprises a signal mismatch compensation unit configured to detect gain error and phase error between an In-phase (I) signal and a Quadrature (Q) signal received through the receiver, to reject image signals existing in the I and Q signals, and to output a result. The signal mismatch compensation unit detects the gain error and the phase error using an adaptive step method of reducing the step size of the gain error and the phase error step by step whenever the gain error and the phase error are converged.According to the present invention, high image rejection ratio is achieved and the adaptation time taken to obtain a high image rejection ratio is reduced simultaneously. Further, a bad influence of the DC offset on the image rejection ratio can be prevented by removing DC offset signals in a digital structure, accordingly, error can be accurately estimated.

    摘要翻译: 本发明涉及一种用于拒绝接收机中的图像的装置。 本发明的装置涉及一种用于拒绝直接转换结构的接收机中的图像信号的装置,并且包括:信号失配补偿单元,被配置为检测同相(I)信号和正交(I)信号之间的增益误差和相位误差, Q)信号,以消除存在于I和Q信号中的图像信号,并输出结果。 信号失配补偿单元使用自适应步长法,在增益误差和相位误差收敛的情况下逐步减小增益误差的步长和相位误差来检测增益误差和相位误差。 根据本发明,实现了高的图像抑制比,同时降低了获得高的图像抑制比所需的适应时间。 此外,通过去除数字结构中的DC偏移信号,可以防止DC偏移对图像抑制比的不良影响,因此可以准确地估计误差。

    APPARATUS FOR REJECTING IMAGE IN RECEIVER
    8.
    发明申请
    APPARATUS FOR REJECTING IMAGE IN RECEIVER 失效
    用于拒绝接收器中的图像的装置

    公开(公告)号:US20110182388A1

    公开(公告)日:2011-07-28

    申请号:US12695860

    申请日:2010-01-28

    IPC分类号: H04L27/08

    摘要: The present invention relates to an apparatus for rejecting images in a receiver.The apparatus of the present invention relates to an apparatus for rejecting image signals in a receiver of a direct conversion structure and comprises a signal mismatch compensation unit configured to detect gain error and phase error between an In-phase (I) signal and a Quadrature (Q) signal received through the receiver, to reject image signals existing in the I and Q signals, and to output a result. The signal mismatch compensation unit detects the gain error and the phase error using an adaptive step method of reducing the step size of the gain error and the phase error step by step whenever the gain error and the phase error are converged.According to the present invention, high image rejection ratio is achieved and the adaptation time taken to obtain a high image rejection ratio is reduced simultaneously. Further, a bad influence of the DC offset on the image rejection ratio can be prevented by removing DC offset signals in a digital structure, accordingly, error can be accurately estimated.

    摘要翻译: 本发明涉及一种用于拒绝接收机中的图像的装置。 本发明的装置涉及一种用于拒绝直接转换结构的接收机中的图像信号的装置,并且包括:信号失配补偿单元,被配置为检测同相(I)信号和正交(I)信号之间的增益误差和相位误差, Q)信号,以消除存在于I和Q信号中的图像信号,并输出结果。 信号失配补偿单元使用自适应步长法,在增益误差和相位误差收敛的情况下逐步减小增益误差的步长和相位误差来检测增益误差和相位误差。 根据本发明,实现了高的图像抑制比,同时降低了获得高的图像抑制比所需的适应时间。 此外,通过去除数字结构中的DC偏移信号,可以防止DC偏移对图像抑制比的不良影响,因此可以准确地估计误差。